CN102732608A - 一种诊断肝癌的标记物及其应用 - Google Patents
一种诊断肝癌的标记物及其应用 Download PDFInfo
- Publication number
- CN102732608A CN102732608A CN2012100910332A CN201210091033A CN102732608A CN 102732608 A CN102732608 A CN 102732608A CN 2012100910332 A CN2012100910332 A CN 2012100910332A CN 201210091033 A CN201210091033 A CN 201210091033A CN 102732608 A CN102732608 A CN 102732608A
- Authority
- CN
- China
- Prior art keywords
- cyp17a1
- liver cancer
- albumen
- serum
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/80—Cytochromes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210091033.2A CN102732608B (zh) | 2011-03-31 | 2012-03-30 | 一种诊断肝癌的标记物及其应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110079327 | 2011-03-31 | ||
CN201110079327.9 | 2011-03-31 | ||
CN201210091033.2A CN102732608B (zh) | 2011-03-31 | 2012-03-30 | 一种诊断肝癌的标记物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102732608A true CN102732608A (zh) | 2012-10-17 |
CN102732608B CN102732608B (zh) | 2014-12-10 |
Family
ID=46929483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210091033.2A Active CN102732608B (zh) | 2011-03-31 | 2012-03-30 | 一种诊断肝癌的标记物及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20140100127A1 (zh) |
CN (1) | CN102732608B (zh) |
WO (1) | WO2012130165A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102944456A (zh) * | 2012-11-07 | 2013-02-27 | 西北农林科技大学 | 一种观察早期胚胎体内发育时空分布的组织切片的制备方法及应用 |
CN107505295A (zh) * | 2017-07-21 | 2017-12-22 | 江苏先思达生物科技有限公司 | 一种肝癌监测试剂盒及其使用方法 |
CN107727864A (zh) * | 2016-07-01 | 2018-02-23 | 首都医科大学附属北京佑安医院 | 一种检测血清中异常脱羧凝血酶原的蛋白芯片、试剂盒及其制备方法 |
CN108004313A (zh) * | 2017-12-20 | 2018-05-08 | 新疆医科大学第附属医院 | 早发冠心病致病基因及其体外检测的试剂、制剂或试剂盒和应用 |
CN108701171A (zh) * | 2015-10-22 | 2018-10-23 | 马古苏托科技大学 | 在通过抑制cyp17a1和cyp19a1治疗癌症中具有应用的药效团、化合物和方法 |
CN109557317A (zh) * | 2019-01-10 | 2019-04-02 | 南方医科大学南方医院 | Atxn2l作为辅助评估胃癌奥沙利铂继发性耐药的标志物的应用 |
CN111349704A (zh) * | 2020-03-17 | 2020-06-30 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107604064B (zh) * | 2017-09-21 | 2021-09-28 | 复旦大学附属肿瘤医院 | Ccl20在肿瘤化疗疗效评估和肿瘤治疗中的应用 |
CN112048556B (zh) * | 2020-08-11 | 2022-07-12 | 北京华奥铂瑞赛思医疗科技有限公司 | 原发性肝细胞肝癌分子分型及生存风险基因群及诊断产品和应用 |
CN114032281A (zh) * | 2021-09-15 | 2022-02-11 | 陈翠英 | 一种丙肝肝癌检测试剂及其在丙肝肝癌检测中的应用 |
CN114058673A (zh) * | 2021-09-15 | 2022-02-18 | 江苏先思达生物科技有限公司 | 一种脂肪肝检测试剂及其在脂肪肝检测中的应用 |
CN113957149B (zh) * | 2021-11-10 | 2024-03-19 | 远见生物科技(上海)有限公司 | 一种检测甲胎蛋白基因和pgr13基因表达量的试剂盒及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058623A1 (en) * | 2005-11-21 | 2007-05-24 | Singapore Health Services Pte Ltd | Methods of predicting hepatocellular carcinoma recurrence by the determination of hepatocellular carcinoma recurrence-associated molecular biomarkers |
WO2007123772A2 (en) * | 2006-03-31 | 2007-11-01 | Genomic Health, Inc. | Genes involved in estrogen metabolism |
CN101608230A (zh) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | 子宫癌遗传检测试剂盒 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353415B2 (en) * | 2006-12-19 | 2016-05-31 | Thomson Reuters (Scientific) Llc | Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom |
-
2012
- 2012-03-30 US US14/008,250 patent/US20140100127A1/en not_active Abandoned
- 2012-03-30 WO PCT/CN2012/073356 patent/WO2012130165A1/zh active Application Filing
- 2012-03-30 CN CN201210091033.2A patent/CN102732608B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058623A1 (en) * | 2005-11-21 | 2007-05-24 | Singapore Health Services Pte Ltd | Methods of predicting hepatocellular carcinoma recurrence by the determination of hepatocellular carcinoma recurrence-associated molecular biomarkers |
WO2007123772A2 (en) * | 2006-03-31 | 2007-11-01 | Genomic Health, Inc. | Genes involved in estrogen metabolism |
CN101608230A (zh) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | 子宫癌遗传检测试剂盒 |
Non-Patent Citations (5)
Title |
---|
《Journal of the National Cancer Institute》 20011231 Ming-Whei Yu ET AL Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men 1644-1651 1-22 第93卷, 第21期 * |
LAURA ROSSI ET AL: "Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients", 《JOURNAL OF HEPATOLOGY》 * |
MING-WHEI YU ET AL: "Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case–Control Study Among Men", 《JOURNAL OF THE NATIONAL CANCER INSTITUTE》 * |
PEN-HUI YIN ET AL: "Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females", 《CANCER LETTERS》 * |
朱明明等: "CYP17 基因多态性与乙型肝炎病毒感染后肝硬化、肝细胞癌的关系", 《山东大学学报(医学版)》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102944456A (zh) * | 2012-11-07 | 2013-02-27 | 西北农林科技大学 | 一种观察早期胚胎体内发育时空分布的组织切片的制备方法及应用 |
CN108701171A (zh) * | 2015-10-22 | 2018-10-23 | 马古苏托科技大学 | 在通过抑制cyp17a1和cyp19a1治疗癌症中具有应用的药效团、化合物和方法 |
CN108701171B (zh) * | 2015-10-22 | 2022-06-10 | 马古苏托科技大学 | 在通过抑制cyp17a1和cyp19a1治疗癌症中具有应用的药效团、化合物和方法 |
CN107727864A (zh) * | 2016-07-01 | 2018-02-23 | 首都医科大学附属北京佑安医院 | 一种检测血清中异常脱羧凝血酶原的蛋白芯片、试剂盒及其制备方法 |
CN107505295A (zh) * | 2017-07-21 | 2017-12-22 | 江苏先思达生物科技有限公司 | 一种肝癌监测试剂盒及其使用方法 |
CN108004313A (zh) * | 2017-12-20 | 2018-05-08 | 新疆医科大学第附属医院 | 早发冠心病致病基因及其体外检测的试剂、制剂或试剂盒和应用 |
CN108004313B (zh) * | 2017-12-20 | 2021-03-16 | 新疆医科大学第一附属医院 | 早发冠心病致病基因及其体外检测的试剂、制剂或试剂盒和应用 |
CN109557317A (zh) * | 2019-01-10 | 2019-04-02 | 南方医科大学南方医院 | Atxn2l作为辅助评估胃癌奥沙利铂继发性耐药的标志物的应用 |
CN111349704A (zh) * | 2020-03-17 | 2020-06-30 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN102732608B (zh) | 2014-12-10 |
US20140100127A1 (en) | 2014-04-10 |
WO2012130165A1 (zh) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102732608B (zh) | 一种诊断肝癌的标记物及其应用 | |
JP6983746B2 (ja) | 葉酸受容体1の検出用の抗体及びアッセイ | |
JP4368110B2 (ja) | 癌患者の生物学的流体中のサバイビンの検出 | |
US7776518B2 (en) | Detection of survivin in the biological fluids of cancer patients | |
WO2014061419A1 (ja) | 新規癌マーカーおよびその利用 | |
JP6890581B2 (ja) | Cd37の検出のための抗体およびアッセイ | |
Neal et al. | Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding | |
CN101512345A (zh) | 包括hccr-1的乳腺癌预后标志物和诱导肥胖的组合物 | |
KR100740761B1 (ko) | 단백질 | |
JP2020528138A (ja) | 肝疾患予測又は診断用組成物及びこれを用いた肝疾患予測又は診断方法 | |
KR101777259B1 (ko) | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
KR101777254B1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
CN102803968A (zh) | 食道癌标志物 | |
CN102778566B (zh) | Dlk1在肝癌诊断及预后判断中的应用 | |
CN105753960B (zh) | 一种肿瘤标志物及其应用 | |
WO2016065877A1 (zh) | Cd166作为肝癌诊断血清标志物的应用及其试剂盒 | |
CN1712542B (zh) | 肝细胞癌相关的蛋白质分子标记原癌蛋白18的筛选及其应用 | |
JP2022521534A (ja) | 乳がんのバイオマーカとしてのbmmf1 repタンパク質の使用 | |
JP5229866B2 (ja) | 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法 | |
EP3594227A1 (en) | Immunogenic fragment peptide of en2 protein or antibody composition specifically recognizing same | |
KR102685696B1 (ko) | 암 전이 및 재발 진단용 조성물 | |
CN110865184B (zh) | Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品 | |
JPWO2010117010A1 (ja) | 腫瘍マーカーおよびその利用 | |
Demichelis et al. | Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature | |
US7928188B2 (en) | Antigen polypeptide for the diagnosis and/or treatment of ovarian cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Mujun Inventor after: Wang Feng Inventor after: Xing Zhen Inventor after: Da Liang Inventor after: Xu Ying Inventor after: Li Zaiping Inventor after: Wang Hongfei Inventor before: Zhao Mujun Inventor before: Wang Feng Inventor before: Xing Zhen Inventor before: Da Liang Inventor before: Xu Ying Inventor before: Li Zaiping |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200727 Address after: 200031 building 35, No. 320, Yueyang Road, Xuhui District, Shanghai Patentee after: Center for excellence and innovation of molecular cell science, Chinese Academy of Sciences Address before: 200031 Yueyang Road, Shanghai, No. 319, No. Patentee before: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES |